Yisaipu® Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation

• मुख्य लेखकों: Hongjuan Lu (लेखक), Yuanqiong Wang (लेखक), Xiuwen Wang (लेखक), Xin Wu (लेखक), Ling Zhou (लेखक), Li Lin (लेखक), Rong Sheng (लेखक), Haoran Tian (लेखक), Ting Li (लेखक), Huji Xu (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Objectives: Anti-tumor necrosis factor (TNF) agents have been regarded as the most effective treatment for ankylosing spondylitis (AS) so far. However, economic factors limited the prescription of original biologicals in China. Yisaipu® is a biosimilar for etanercept as pre fill syringes (PFS), whic...